PMID- 20712569
OWN - NLM
STAT- MEDLINE
DCOM- 20110126
LR  - 20220317
IS  - 1875-533X (Electronic)
IS  - 0929-8673 (Linking)
VI  - 17
IP  - 29
DP  - 2010
TI  - Interleukin-18: biology and role in the immunotherapy of cancer.
PG  - 3353-7
AB  - Interleukin-18 (IL-18) is an immunostimulatory cytokine belonging to the IL-1 
      family. IL-18 can regulate both innate and adaptive immune responses through its 
      effects on natural killer (NK) cells, monocytes, dendritic cells, T cells, and B 
      cells. IL-18 acts synergistically with other pro-inflammatory cytokines to 
      promote interferon-gamma (IFN-gamma) production by NK cells, T cells, and possibly other 
      cell types. Systemic administration of IL-18 has been shown to have significant 
      antitumor activity in several preclinical animal models. Phase I clinical trials 
      of recombinant human IL-18 have demonstrated that it can be safely administered 
      to patients with advanced cancer. Biologic effects of IL-18 therapy include 
      activation of monocytes, NK cells, and T cells and production of IFN-gamma as well as 
      other cytokines in vivo. A phase II study of IL-18 in patients with metastatic 
      melanoma confirmed its safety but suggested limited efficacy of IL-18 monotherapy 
      in this setting. IL-18 appears to act predominantly as a costimulatory cytokine 
      and its optimal use for cancer immunotherapy may be in combination with other 
      immunostimulatory cytokines, vaccines, or monoclonal antibodies.
FAU - Srivastava, S
AU  - Srivastava S
AD  - Bone Marrow and Stem Cell Transplantation Program, Division of 
      Hematology/Oncology, Department of Medicine, Indiana University School of 
      Medicine, Indianapolis, IN 46202, USA. srivasts@iupui.edu
FAU - Salim, N
AU  - Salim N
FAU - Robertson, M J
AU  - Robertson MJ
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United Arab Emirates
TA  - Curr Med Chem
JT  - Current medicinal chemistry
JID - 9440157
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Interleukin-18)
SB  - IM
MH  - Antineoplastic Agents/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Combined Modality Therapy
MH  - Hematopoietic Stem Cell Transplantation
MH  - Humans
MH  - Interleukin-18/metabolism/physiology/*therapeutic use
MH  - Killer Cells, Natural/immunology/metabolism
MH  - Neoplasms/*drug therapy/metabolism/therapy
MH  - T-Lymphocytes/immunology/metabolism
EDAT- 2010/08/18 06:00
MHDA- 2011/01/28 06:00
CRDT- 2010/08/18 06:00
PHST- 2010/04/29 00:00 [received]
PHST- 2010/07/22 00:00 [accepted]
PHST- 2010/08/18 06:00 [entrez]
PHST- 2010/08/18 06:00 [pubmed]
PHST- 2011/01/28 06:00 [medline]
AID - BSP/CMC/E-Pub/ 213 [pii]
AID - 10.2174/092986710793176348 [doi]
PST - ppublish
SO  - Curr Med Chem. 2010;17(29):3353-7. doi: 10.2174/092986710793176348.